BCRX
Price
$6.82
Change
+$0.41 (+6.40%)
Updated
Apr 11 closing price
Capitalization
1.43B
19 days until earnings call
CLDX
Price
$16.84
Change
+$0.90 (+5.65%)
Updated
Apr 11 closing price
Capitalization
1.12B
19 days until earnings call
Ad is loading...

BCRX vs CLDX

Header iconBCRX vs CLDX Comparison
Open Charts BCRX vs CLDXBanner chart's image
BioCryst Pharmaceuticals
Price$6.82
Change+$0.41 (+6.40%)
Volume$3.11M
Capitalization1.43B
Celldex Therapeutics
Price$16.84
Change+$0.90 (+5.65%)
Volume$805.58K
Capitalization1.12B
BCRX vs CLDX Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. CLDX commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and CLDX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (BCRX: $6.82 vs. CLDX: $16.84)
Brand notoriety: BCRX: Notable vs. CLDX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 85% vs. CLDX: 99%
Market capitalization -- BCRX: $1.43B vs. CLDX: $1.12B
BCRX [@Biotechnology] is valued at $1.43B. CLDX’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 4 TA indicator(s) are bullish while CLDX’s TA Score has 3 bullish TA indicator(s).

  • BCRX’s TA Score: 4 bullish, 5 bearish.
  • CLDX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, both BCRX and CLDX are a bad buy in the short-term.

Price Growth

BCRX (@Biotechnology) experienced а -0.15% price change this week, while CLDX (@Biotechnology) price change was +6.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

CLDX is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.43B) has a higher market cap than CLDX($1.12B). BCRX YTD gains are higher at: -9.309 vs. CLDX (-33.360). BCRX has higher annual earnings (EBITDA): 12.8M vs. CLDX (-191.9M). CLDX has more cash in the bank: 725M vs. BCRX (321M). CLDX has less debt than BCRX: CLDX (3.81M) vs BCRX (809M). BCRX has higher revenues than CLDX: BCRX (451M) vs CLDX (7.02M).
BCRXCLDXBCRX / CLDX
Capitalization1.43B1.12B127%
EBITDA12.8M-191.9M-7%
Gain YTD-9.309-33.36028%
P/E RatioN/AN/A-
Revenue451M7.02M6,425%
Total Cash321M725M44%
Total Debt809M3.81M21,217%
FUNDAMENTALS RATINGS
BCRX vs CLDX: Fundamental Ratings
BCRX
CLDX
OUTLOOK RATING
1..100
7253
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
58
Fair valued
PROFIT vs RISK RATING
1..100
6865
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
6091
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (30) in the Biotechnology industry is in the same range as CLDX (58). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (65) in the Biotechnology industry is in the same range as BCRX (68). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.

CLDX's SMR Rating (93) in the Biotechnology industry is in the same range as BCRX (100). This means that CLDX’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (60) in the Biotechnology industry is in the same range as CLDX (91). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CLDX (100). This means that BCRX’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXCLDX
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
72%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
80%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIICX37.010.76
+2.10%
American Funds Intl Gr and Inc 529C
LIESX17.78N/A
N/A
Franklin International Equity IS
BMICX9.21N/A
N/A
BlackRock Managed Income Investor C
NBGUX24.85N/A
N/A
Neuberger Berman Large Cap Growth Adv
SUTAX13.47N/A
N/A
AB Sustainable US Thematic A

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+6.40%
VCYT - BCRX
46%
Loosely correlated
+5.12%
OCGN - BCRX
39%
Loosely correlated
+3.11%
COGT - BCRX
37%
Loosely correlated
+5.97%
ARWR - BCRX
36%
Loosely correlated
+6.12%
CLDX - BCRX
36%
Loosely correlated
+5.65%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with DNLI. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+5.65%
DNLI - CLDX
51%
Loosely correlated
+1.60%
KYMR - CLDX
49%
Loosely correlated
+7.68%
BEAM - CLDX
48%
Loosely correlated
+5.74%
ATXS - CLDX
46%
Loosely correlated
-0.49%
NUVB - CLDX
46%
Loosely correlated
+13.71%
More